TR200002097A2 - Triazol ve imidazol türevleri - Google Patents

Triazol ve imidazol türevleri

Info

Publication number
TR200002097A2
TR200002097A2 TR2000/02097A TR200002097A TR200002097A2 TR 200002097 A2 TR200002097 A2 TR 200002097A2 TR 2000/02097 A TR2000/02097 A TR 2000/02097A TR 200002097 A TR200002097 A TR 200002097A TR 200002097 A2 TR200002097 A2 TR 200002097A2
Authority
TR
Turkey
Prior art keywords
triazole
imidazole derivatives
compounds
pharmaceutically acceptable
general formula
Prior art date
Application number
TR2000/02097A
Other languages
English (en)
Other versions
TR200002097A3 (tr
Inventor
Alanine Alexander
B�Ttelmann Bernd
Heitz Neidhart Mar�E-Paule
Jaeschke Georg
Pinard Emmanuel
Wyler Rene
Original Assignee
F.Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag filed Critical F.Hoffmann-La Roche Ag
Publication of TR200002097A2 publication Critical patent/TR200002097A2/tr
Publication of TR200002097A3 publication Critical patent/TR200002097A3/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Abstract

Mevcut bulus, asagidaki genel formülün bilesikleri ile ilgilidir: ve bunlarin farmasötik açidan kabul edilebilir asit ilave tuzlarini simgeler. Bu bilesikler, NMDA reseptör alt tipi selektif blokerleri ile iliskili hastaliklarin tedavisi için kullanilabilir.
TR2000/02097A 1999-07-21 2000-07-19 Triazol ve imidazol türevleri TR200002097A3 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99114313 1999-07-21

Publications (2)

Publication Number Publication Date
TR200002097A2 true TR200002097A2 (tr) 2001-02-21
TR200002097A3 TR200002097A3 (tr) 2001-02-21

Family

ID=8238635

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/02097A TR200002097A3 (tr) 1999-07-21 2000-07-19 Triazol ve imidazol türevleri

Country Status (29)

Country Link
US (1) US6265426B1 (tr)
EP (1) EP1070708B1 (tr)
JP (1) JP3628946B2 (tr)
KR (1) KR100383776B1 (tr)
CN (1) CN1148357C (tr)
AR (1) AR024790A1 (tr)
AT (1) ATE257827T1 (tr)
AU (1) AU773463B2 (tr)
BR (1) BR0003075A (tr)
CA (1) CA2314009C (tr)
CO (1) CO5190713A1 (tr)
DE (1) DE60007697T2 (tr)
DK (1) DK1070708T3 (tr)
ES (1) ES2211420T3 (tr)
HR (1) HRP20000482A2 (tr)
HU (1) HUP0002792A3 (tr)
ID (1) ID26599A (tr)
IL (1) IL137328A0 (tr)
MA (1) MA26747A1 (tr)
MX (1) MXPA00007069A (tr)
NO (1) NO20003723L (tr)
NZ (1) NZ505766A (tr)
PE (1) PE20010349A1 (tr)
PL (1) PL341616A1 (tr)
PT (1) PT1070708E (tr)
SG (1) SG98422A1 (tr)
TR (1) TR200002097A3 (tr)
UY (1) UY26253A1 (tr)
ZA (1) ZA200003680B (tr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962490A (en) * 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US6610723B2 (en) 2001-01-29 2003-08-26 Hoffmann-La Roche Inc. Imidazole derivatives
US7375136B2 (en) 2001-03-08 2008-05-20 Emory University pH-dependent NMDA receptor antagonists
US6951875B2 (en) * 2001-10-29 2005-10-04 Hoffmann-La Roche Inc. Conjugated aromatic compounds with a pyridine substituent
US7005432B2 (en) * 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
CA2488117A1 (en) 2002-06-17 2003-12-24 Merck & Co., Inc. 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists
US20060004088A1 (en) * 2002-10-22 2006-01-05 Oct Inc. Furan derivatives for preventing and curing osteoporosis and pharmaceutical compositions containing the same
US7084145B2 (en) * 2002-10-25 2006-08-01 Pfizer Inc. Triazole compounds useful in therapy
CN1747936A (zh) * 2003-02-12 2006-03-15 特兰斯泰克制药公司 作为治疗试剂的取代吡咯衍生物
GB0303503D0 (en) * 2003-02-14 2003-03-19 Novartis Ag Organic compounds
GB0315111D0 (en) 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
DE602004027301D1 (de) * 2003-12-22 2010-07-01 Merck Sharp & Dohme Alpha-hydroxyamide als bradykininantagonisten oder inverse agonisten
NZ548208A (en) * 2004-02-12 2010-09-30 Transtech Pharma Inc Substituted azole derivatives, compositions, and methods of use
CN101374835B (zh) * 2006-01-30 2012-04-25 转化技术制药公司 作为PTPase抑制剂的取代的咪唑衍生物、组合物和使用方法
JO3019B1 (ar) * 2006-04-19 2016-09-05 Janssen Pharmaceutica Nv ثلاثي مستبدل 4،2،1-ثلاثي زولات
EP2118077B1 (en) 2007-02-08 2014-12-24 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
EP2529623A3 (en) * 2007-04-03 2013-03-13 E. I. du Pont de Nemours and Company Substituted benzene fungicides
US20110158907A1 (en) * 2007-04-19 2011-06-30 The Trustees Of The Univeristy Of Pennsylvania Diphenyl-heteroaryl derivatives and their use for binding and imaging amyloid plaques
US8420680B2 (en) * 2007-06-29 2013-04-16 Emory University NMDA receptor antagonists for neuroprotection
JO2784B1 (en) 2007-10-18 2014-03-15 شركة جانسين فارماسوتيكا ان. في 5,3,1 - Triazole substitute derivative
RU2474579C2 (ru) 2007-10-18 2013-02-10 Янссен Фармацевтика Нв Тризамещенные 1,2,4-триазолы
AU2009226988B2 (en) 2008-03-19 2013-05-23 Janssen Pharmaceutica Nv Trisubstituted 1, 2, 4 -triazoles as nicotinic acetylcholine receptor modulators
WO2009118187A1 (en) * 2008-03-27 2009-10-01 Evotec Neurosciences Gmbh Methods for treating disorders using nmda nr2b-subtype selective antagonist
JP5486591B2 (ja) 2008-05-09 2014-05-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ アセチルコリン受容体モジュレーターとしての三置換ピラゾール
RU2532394C1 (ru) * 2013-10-29 2014-11-10 Общество с ограниченной ответственностью "Научно-производственное объединение "Фарматрон" (НПО "Фарматрон") ПРИМЕНЕНИЕ БРОМИДА 1-β-ФЕНИЛЭТИЛ)-4-АМИНО-1,2,4-ТРИАЗОЛИЯ (ГИПЕРТРИЛ) КАК АКТИВНОЙ ОСНОВЫ ЛЕКАРСТВЕННЫХ СРЕДСТВ ДЛЯ КОРРЕКЦИИ НАРУШЕНИЙ ФУНКЦИОНИРОВАНИЯ НИТРОКСИДЕРГИЧЕСКОЙ СИСТЕМЫ ОРГАНОВ-МИШЕНЕЙ ПРИ ГОМОЦИСТЕИНЕМИИ И ОСТРЫХ НАРУШЕНИЯХ МОЗГОВОГО КРОВООБРАЩЕНИЯ
BR112017003918B1 (pt) 2014-08-29 2022-05-03 Fmc Corporation Composto, composições e mistura herbicida e método para o controle do crescimento da vegetação
KR102512548B1 (ko) 2017-12-22 2023-03-22 삼성디스플레이 주식회사 유기 전계 발광 소자 및 유기 전계 발광 소자용 함질소 화합물
US11912670B1 (en) 2023-10-25 2024-02-27 King Faisal University Ethyl 4-(5-(3-fluorophenyl)-4-phenyl-4H-1,2,4-triazol-3-ylthio)butanoate as an antimicrobial compound

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1579352A (en) * 1977-05-06 1980-11-19 Lepetit Spa 3,5-disubstituted-1h-1,2,4-triazoles
DE19643037A1 (de) * 1996-10-18 1998-04-23 Boehringer Ingelheim Kg Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
AU744297B2 (en) * 1997-07-03 2002-02-21 Neurogen Corporation Certain diarylimidazole derivatives; a new class of NPY specific ligands
DE19816880A1 (de) * 1998-04-17 1999-10-21 Boehringer Ingelheim Pharma Neue Diphenyl-substituierte 5-Ring-Heterocyclen, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
US7487474B2 (en) 2003-01-02 2009-02-03 Pdf Solutions, Inc. Designing an integrated circuit to improve yield using a variant design element

Also Published As

Publication number Publication date
UY26253A1 (es) 2000-10-31
NO20003723L (no) 2001-01-22
ES2211420T3 (es) 2004-07-16
AU773463B2 (en) 2004-05-27
JP2001064263A (ja) 2001-03-13
CN1148357C (zh) 2004-05-05
ZA200003680B (en) 2001-01-22
CA2314009A1 (en) 2001-01-21
AU4865100A (en) 2001-01-25
EP1070708B1 (en) 2004-01-14
TR200002097A3 (tr) 2001-02-21
NZ505766A (en) 2002-03-28
KR100383776B1 (ko) 2003-05-12
PT1070708E (pt) 2004-05-31
NO20003723D0 (no) 2000-07-20
ID26599A (id) 2001-01-25
DK1070708T3 (da) 2004-05-10
KR20010049825A (ko) 2001-06-15
AR024790A1 (es) 2002-10-23
BR0003075A (pt) 2001-03-13
CN1281852A (zh) 2001-01-31
ATE257827T1 (de) 2004-01-15
SG98422A1 (en) 2003-09-19
HUP0002792A2 (hu) 2001-09-28
MA26747A1 (fr) 2004-12-20
US6265426B1 (en) 2001-07-24
IL137328A0 (en) 2001-07-24
DE60007697T2 (de) 2004-12-09
DE60007697D1 (de) 2004-02-19
EP1070708A1 (en) 2001-01-24
PE20010349A1 (es) 2001-03-26
MXPA00007069A (es) 2002-04-24
HU0002792D0 (en) 2000-09-28
PL341616A1 (en) 2001-01-29
JP3628946B2 (ja) 2005-03-16
CA2314009C (en) 2008-09-30
CO5190713A1 (es) 2002-08-29
HUP0002792A3 (en) 2002-10-28
HRP20000482A2 (en) 2001-06-30

Similar Documents

Publication Publication Date Title
TR200002097A2 (tr) Triazol ve imidazol türevleri
JO2503B1 (en) Benzathiazole derivatives
ATE382044T1 (de) Imidazol- derivate
MX2007003329A (es) Derivados heterociclicos y biciclicos y su uso como inhibidores de estearoil-coa-desaturasa (scd).
TR200103607T2 (tr) Pürin Türevleri
MX2007003332A (es) Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa.
TR200201001T2 (tr) Pürin türevleri
ATE301651T1 (de) Substituierte benzimidazole
TR200000520A2 (tr) 4-Fenil-piridin türevleri.
NO20011721D0 (no) N-aralkylaminotetraliner som ligander for neuropeptid Y Y5 reseptor
ATE349432T1 (de) 2-anilino-pyrimidin-derivate als cyclin-abhängige kinase hemmer
ATE254110T1 (de) Antiproliferative imidazol wirkstoffe
BR9711342A (pt) Antagonistas de receptor de bombesina nÆo-pept¡do
TR200300766T2 (tr) A1 adenosin reseptörü antagonistleri olarak yoğunlaştırılmış purin türevleri.
DK1246808T3 (da) 1,2-diarylbenzimidazoler til behandling af sygdomme, som er associeret med en mikroglia-aktivering
IT1255802B (it) Derivati imidazolici ad attivita' a ii antagonista
TR200001452T2 (tr) Bifenilamidin türevleri.
RS20060072A (en) Aminoquinoline derivatives and their use as adenosine a3 ligands
NO20002655L (no) 5-(2-imidazolinylamino) -benzimidazol derivater, fremstilling og anvendelse derav som <alfa>-adrenoceptoragonister med forbedret metabolisk stabilitet
DK1204658T3 (da) Benzofurylpiperazin-serotoninagonister
HK1053109A1 (en) Substituted homopiperidinyl benzimidazole compounds, pharmaceutical compositions comprising the same, methods for preparing them and the use for the preparation of a medicament of them
DE69828390D1 (de) Diaminotrifluoromethylpyrimidinderivate enthaltende antikrebs-zusammensetzung
NO883263D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive benzimidazol-derivater.
DE69913652D1 (de) Adamantancarboximidamid-derivate und ihre anwendung als nmda-antagonisten
NZ504124A (en) Phenyl-alkyl-imidazoles and use in treating inflammatory disease